Getting tested for bladder cancer — which involves the use of a catheter — can be rather invasive and somewhat painful, says Forbes' Peter Cohan. So biotech startup Predictive Biosciences says it has come up with a better way. The company has commercialized a urine-based, non-invasive cancer detection technology invented by two researchers that uses a combination of protein and DNA biomarkers to help clinicians diagnose bladder and prostate cancer, Cohan says. Because of the potential size of the target markets — a $3 billion bladder cancer detection market and a $3 billion prostate cancer detection market — Predictive Biosciences has raised $57 million in venture capital. The company doesn't sell its diagnostics to urologists, it does test urine samples from patients at its own lab, Cohan adds. The company acquired an anatomic pathology lab in Cleveland in January 2010, focused on urology.
This Won't Hurt a Bit
May 25, 2011